Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1978 Jun;1(3):98-103.
doi: 10.1159/000213927.

[Immuno-chemotherapy in Patients With Disseminated Metastasizing Stage III Melanoma. Randomized Study With methyl-CCNU Versus C. Parvum Plus methyl-CCNU]

[Article in German]
Clinical Trial

[Immuno-chemotherapy in Patients With Disseminated Metastasizing Stage III Melanoma. Randomized Study With methyl-CCNU Versus C. Parvum Plus methyl-CCNU]

[Article in German]
E M Kokoschka et al. Onkologie. .

Abstract

34 patients with disseminated malignant melanoma (stage III) were randomized to the following therapy groups: Chemotherapy (MeCCNU, NSC 99441; 200 mg/m2, given orally every 8 weeks), or immuno-chemotherapy (1 mg Corynebacterium parvum i.v., on days 1-4 + MeCCNU 200 mg/m2 on day 8, repeated every 7 weeks). Total therapy response rate was 33%; total and partial remissions were achieved in 26% of the patients receiving chemotherapy, and in 40% under immuno-chemotherapy. Interim life table analysis shows that in the group receiving C. parvum + MeCCNU 50% of the patients survived more than 12 months, whereas in the group with MeCCNU survival of 50% was 6 months. Pretreatment with C. parvum did not only potentiate the therapeutic effect, but also reduce the myelosuppression of MeCCNU.

Similar articles

See all similar articles

Cited by 1 article

  • Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S. Pasquali S, et al. Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2. Cochrane Database Syst Rev. 2018. PMID: 29405038 Free PMC article. Review.
Feedback